IV fosnetupitant/palonosetron
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for IV fosnetupitant/palonosetron, covering 2020-04-15 to 2020-04-15. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer [Phase 3]